Качество на живот, свързано със здравето, при миастения гравис

  • Валентина Игнатова
Keywords: миастения гравис, качество на живот, свързано със здравето, препоръки

Abstract

Миастения гравис (МГ) е сравнително рядко, но недостатъчно проучено заболяване със социална значимост, за което особено дефицитни в световен мащаб са данните за качеството на живот, свързано със здравето, (КЖСЗ) и социално-икономическата тежест.

Целта на настоящия обзор е да представи обобщение на резултатите за КЖСЗ при МГ, докладвани в достъпните съвременни литературни източници, както и да очертае стратегии за неговото подобряване.

Публикуваните данни за КЖСЗ варират по страни, като роля за това оказват и различията в използваната методология. Установена е сигнификантна връзка между клиничните фактори и КЖСЗ. По-лошо КЖСЗ се отчита при по-висока честота на симптомите и тежестта на изява, при по-високо ниво на инвалидност, както и при булбарна или генерализирана манифестация. Загубата на трудовата заетост и наличието на депресия са по-достоверни предиктори за влошено КЖСЗ при пациентите с MГ, отколкото тежестта на физическите симптоми. Наличието на коморбидност се отразява неблагоприятно върху КЖСЗ, особено в психоемоционален и ментален аспект.

Навременната и адекватна терапия при МГ, водеща до редукция на инвалидността, се свързва с по-добро КЖСЗ. Правилният медицински подход оптимизира най-вече физическите аспекти на КЖСЗ, докато за намаляване на психоемоционалните симптоми се препоръчва психосоциална рехабилитация, каквато все още не е въведена в много страни, включително и в България.

References

Национален консенсус за диагностика и лечение на myasthenia gravis. Под редакцията на акад. И. Миланов и доц. М. Миланова, София, март 2021.
Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundationof America. Neurology. 2000;55:16–23.
Cioncoloni D, Casali S, Ginanneschi F, et al. Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients. Neurol Sci. 2016 May;37(5):717-23.
Conti-Fine BM, Diethelm-Okita B, Ostlie N, et al. Immunopathogenesis of myasthenia gravis. In: Kaminski HJ, ed. Myasthenia gravis and related disorders. New York: Humana Press. 2009:43-70.
Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2021;357(9274):2122–8.
Tsonis AI, Zisimopoulou P, Lazaridis K, et al. MuSK autoantibodies in myasthenia gravis detected by cell-based assay—a multinational study. J Neuroimmunol, 2015; 284:10–17.
Boscoe AN, Xin H, LʼItalien GJ, et al. Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life. J Clin Neuromuscul Dis. 2019 Jun;20(4):173-181.
Gill TM, Feinstein AR. A critical appraisal of the qualityof quality-of-life measurements. JAMA. 1994; 272:619–626.
Skevington SM, Lotfy M, O'Connell KA. WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299-310.
Stojanov A, Milošević V, Đorđević G, et al. Quality of Life of Myasthenia Gravis Patients in Regard to Epidemiological and Clinical Characteristics of the Disease. Neurologist. 2019 Jul;24(4):115-120.
Rozmilowska I, Adamczyk-Sowa M, Rutkowska K, et al. Improvement of quality of life after therapeutic plasma exchange in patients with myasthenic crisis. Neurol Neurochir Pol. 2016 Nov-Dec;50(6):418-424.
van der Hiele K, van Gorp DA, Heerings MA, et al. The MS@Workstudy: a 3-year prospective observational study on factors involvedwith work participation in patients with relapsing-remitting multiplesclerosis. BMC Neurol. 2015;15:134.
Alanazy MH, Binabbad RS, Alromaih NI, et al. Severity and depression can impact quality of life in patients with myasthenia gravis. Muscle Nerve. 2020 Jan;61(1):69-73.
Barnett C, Wilson G, Barth D, et al. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):94-7.
Busch C, Machens A, Pichlmeier U, et al. Long-term outcome and quality of life after thymectomy for myasthenia gravis. Ann Surg. 1996; 224:225-32.
Ostovan VR, Fatehi F, Davoudi F, et al. Validation of the 15-item myasthenia gravis quality of life questionnaire (MG-QOL15) Persian version. Muscle Nerve. 2016 Jun;54(1):65-70.
Mourão AM, Gomez RS, Barbosa LS, et al. Determinants of quality of life in Brazilian patients with myasthenia gravis. Clinics (Sao Paulo). 2016 Jul;71(7):370-4.
Ignatova V, Kostadinov K, Vassileva E, et al. Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria. Front Public Health. 2022 Mar 3;10:822909.
Birnbaum S, Ghout I, Demeret S, et al. Translation, cross-cultural adaptation, and validation of the French version of the 15-item Myasthenia Gravis Quality Of life scale. Muscle Nerve. 2017 May;55(5):639-645.
Raggi A, Leonardi M, Ayadi R, et al. Validation of the italian version of the 15-item Myasthenia Gravis Quality-of-Life questionnaire. Muscle Nerve. 2017 Oct;56(4):716-720.
Miao X, Lian Z, Liu J, et al. Translation, cross-cultural adaptation, and validation of the Chinese version of the 15-item myasthenia gravis quality of life questionnaire. Muscle Nerve. 2019 Jan;59(1):95-99.
Taşcilar NF, Saraçli Ö, Kurçer MA, et al. Reliability and validity of the Turkish version of myastheniagravis-quality of life questionnaire-15 item. Turk J Med Sci. 2016 Jun 23;46(4):1107-13.
Alanazy MH, Abuzinadah AR, Muayqil T. Translation and validation of the Arabic version of the revised 15-item myasthenia gravis quality-of-life questionnaire. Muscle Nerve. 2018 Apr;57(4):581-585.
Kumar R, Nagappa M, Sinha S, et al. MG-QoL-15 scores in treated myasthenia gravis: Experience from a university hospital in India. Neurol India. 2016 May-Jun;64(3):405-10.
Rozmilowska I, Adamczyk-Sowa M, Pierzchala K, et al. Validity and reliability of the Polish version of myasthenia gravis – Quality of life questionnaire – 15 item. Neurol Neurochir Pol 2017;51(4):311-318.
Twork S, Wiesmeth S, Klewer J, et al. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010 Nov 11;8:129.
Gilchrist JM. Quality-of-Life Issues in Myasthenia Gravis. In: Phillips LH, ed. Update on Myasthenia Gravis. Rochester, MN, American Association of Electrodiagnostic Medicine. 29-35; 2004.
Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis – results from population based cohorts. Health Qual Life Outcomes. 2015 Aug 1;13:115.
Raggi A, Leonardi M, Antozzi C, et al. Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci. 2010 Feb;31(1):41-5.
Kulkantrakorn K, Sawanyawisuth K, Tiamkao S. Factors correlating quality of life in patients with myasthenia gravis. Neurol Sci. 2010 Oct;31(5):571-3.
Leonardi M, Raggi A, Antozzi C, et al. The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. J Neurol. 2010 Jan;257(1):98-102.
Liu CW, Luo M, Mei JD, et al. Perioperative and long-term outcome of thymectomy for myasthenia gravis: comparison of surgical approaches and prognostic analysis. Chin Med J (Engl). 2013 Jan;126(1):34-40.
Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. Muscle Nerve. 2019 Dec;60(6):707-715.
Raggi A, Leonardi M, Mantegazza R, et al. Social support and self-efficacy in patients with Myasthenia Gravis: a common pathway towards positive health outcomes. Neurol Sci. 2010 Apr;31(2):231-5.
Utsugisawa K, Suzuki S, Nagane Y, et al. Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve. 2014 Oct;50(4):493-500.
Winter Y, Schepelmann K, Spottke AE, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010 Sep;257(9):1473-81.
Bykov YN, Okladnikov VI, Smolin AI. [The quality of life in patients with a different types of myasthenia gravis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(1. Vyp. 2):64-69. Russian.
Mazzoli M, Ariatti A, Valzania F, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018 Jan;128(1):15-24.
Padua L, Evoli A, Aprile I, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci. 2001 Oct;22(5):363-9.
Basta IZ, Pekmezovic TD, Peric SZ, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci. 2012; 33(6):1375–81.
Yang Y, Zhang M, Guo J, et al. Quality of life in 188 patients with myasthenia gravis in China. Int J Neurosci. 2016; 126(5):455-62.
Rostedt A, Padua L, Stålberg EV. Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol. 2006 Feb;13(2):191-3.
Braz NFT, Rocha NP, Vieira ÉLM, et al. Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. J Clin Neurosci. 2018 Apr;50:41-44.
Bogdan A, Barnett C, Ali A, AlQwaifly et al. Chronic stress, depression and personality type in patients with myasthenia gravis. Eur J Neurol. 2020 Jan;27(1):204-209.
Pasnoor M, He J, Herbelin L, et al; Methotrexate in MG Investigators of the Muscle Study Group. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016 Jul 5;87(1):57-64.
Kotan V O, Kotan Z, Aydin B, et al. Psychopathology, Psychosocial Factors and Quality of Life in Patients with Myasthenia Gravis. Journal of Neurological Sciences (Turkish). 2016; 33(3).
Bourque PR, Pringle CE, Cameron W, et al. Subcutaneous immunoglobulin therapy in thechronic management of myasthenia gravis: aretrospective cohort study. PLoS One. 2016; 11:e0159993.
Ariatti A, Stefani M, Miceli P, et al. Prognostic factors and health-related quality of life in ocular Myasthenia Gravis (OMG). Int J Neurosci. 2014 Jun;124(6):427-35.
Barnett C, Bril V, Bayoumi AM. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. Eur J Neurol. 2019 Mar;26(3):452-459.
Barnett C, Bril V, Kapral M, et al. Development and validation of the Myasthenia Gravis Impairment Index. Neurology. 2016;87(9):879-886.
Burns TM, Conaway MR, Cutter GR, et al. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008; 38(6):1553-62.
Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988 Nov;235(8):449-53.
Martínez-Lapiscina EH, Erro ME, Ayuso T, et al. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve. 2012 Aug;46(2):174-80.
Burns TM, Graham CD, Rose MR, et al. Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve. 2012 Jul;46(1):9-25.
Suzuki Y, Utsugisawa K, Suzuki S, et al. Factors associated with depressive state in patients with myasthenia gravis: a multicenter crosssectional study. BMJ Open. 2011; 19;1(2):e000313.
Li KK, Qian K, Feng YG, et al. Predictive factors of prolonged mechanical ventilation, overall survival, and quality of life in patients with post-thymectomy myasthenic crisis. World J Surg Oncol. 2017;15(1):150.
Heliopoulos I, Patlakas G, Vadikolias K, et al. Maximal voluntary ventilation in myasthenia gravis. Muscle Nerve. 2003 Jun;27(6):715-9.
Hughes T. The early history of myasthenia gravis. Neuromuscul Disord. 2005 Dec;15(12):878-86.
Fregonezi GA, Regiane-Resqueti V, Pradas J, et al. [The relationship between lung function and health-related quality of life in patients with generalized myasthenia gravis]. Arch Bronconeumol. 2006 May;42(5):218-24. Spanish.
Tran C, Bril V, Katzberg HD, et al. Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle Nerve. 2018 Aug;58(2):197-203.
Rassler B, Hallebach G, Kalischewski P, et al. The effect of respiratory muscle endurance training in patients with myasthenia gravis. Neuromuscul Disord. 2007 May;17(5):385-91.
Wenninger S, Schoser B. [Myasthenia gravis: current status of antibody diagnostics and aspects on refractory myasthenia gravis]. Fortschr Neurol Psychiatr. 2018 Sep;86(9):551-558. German.
Fioravanti G, Casale S, Mantegazza R, et al. Self-Efficacy, Social Support and Locus of control as correlates of Health-Related Quality of Life in Myasthenia Gravis. BPA-Applied Psychology Bulletin. 2010; (261/262):19-27.
Paul RH, Nash JM, Cohen RA, et al. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve. 2001 Apr;24(4):512-6.
Koopman WJ, LeBlanc N, Fowler S, et al. Hope, Coping, and Quality of Life in Adults with Myasthenia Gravis. Can J Neurosci Nurs. 2016;38(1):56-64.
Oliveira EF, Valério BCO, Cavalcante V, et al. Quantitative Myasthenia Gravis Score: a Brazilian multicenter study for translation, cultural adaptation and validation. Arq Neuropsiquiatr. 2017 Jul;75(7):457-463.
Richards HS, Jenkinson E, Rumsey N, et al. The psychosocial impact of ptosis as a symptom of Myasthenia Gravis: a qualitative study. Orbit. 2014; 33(4):263-9.
Stankovic M, Peric S, Stojiljkovic Tamas O, et al. Quality of life in patients with MuSK positive myasthenia gravis. Acta Neurol Belg. 2018; 118(3):423–427.
Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017 Feb 23;7(2):e013278.
Sitek EJ, Bilińska MM, Wieczorek D, et al. Neuropsychological assessment in myasthenia gravis. Neurol Sci. 2009 Feb;30(1):9-14.
Ybarra MI, Kummer A, Frota ER, et al. Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr. 2011 Apr;69(2A):176-9.
Aysal F, Karamustafalioğlu O, Özçelik B, et al. The Relationship of Symptoms of Anxiety and Depression with Disease Severity and Treatment Modality in Myasthenia Gravis: A Cross-sectional Study. Noro Psikiyatr Ars. 2013 Dec;50(4):295-300.
Mullins LL, Carpentier MY, Paul RH, et al; Muscle Study Group. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve. 2008 Aug;38(2):947-56.
Fisher J, Parkinson K, Kothari MJ. Self-reported Depressive Symptoms in Myasthenia Gravis. J Clin Neuromuscul Dis. 2003 Mar;4(3):105-8.
Bekircan-Kurt CE, Kurne A, Ozdamar SE, et al. Myasthenia Gravis; Single Entity, Variable Clinical Features: Ten Years of Clinical Experience in a Tertiary Care Center Ten Years Clinical Experience of a Tertiary Care Center. Journal of Neurological Sciences (Turkish). 2013; 30(1):135-43.
Doering S, Henze T, Schüssler G. Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol. 1993 Jun;50(6):617-20.
Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand. 1988 Apr;77(4):443-5.
Hoffmann S, Ramm J, Grittner U, et al. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016 Aug 2;6(10):e00538.
Chen Y, Chang Y, Chiu H, et al. Psychosocial aspects inmyasthenic patients treated by plasmapheresis. J Neurol. 2011; 258(7):1240–6.
Kalita J, Kohat AK, Misra UK. Predictors of outcome of myasthenic crisis. Neurol Sci. 2014 Jul;35(7):1109-14.
Bacci ED, Coyne KS, Poon JL, et al. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019 Dec 21;19(1):335.
Tigner DC, Rankin JA, Then KL. Self-efficacy theory, quality of life and myasthenia gravis self-management. British Journal of Neuroscience Nursing. 2018; 14(4):171-8.
Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015; 119(7):964-79.
Published
2022-06-01
How to Cite
1.
Игнатова В. Качество на живот, свързано със здравето, при миастения гравис. Редки болести и лекарства сираци [Internet]. 2022Jun.1 [cited 2022Jun.26];13(1):5-13. Available from: https://journal.raredis.org/index.php/RBLS/article/view/157
Section
Статии